Biotech Values

[dewophile]

there is some compelling data for competing companies expected at AASLD. In particular GILD BMY and perhaps MRK may have early data on viable regimens without ribavirin. biotech investors often don't look too far ahead

450 should gain approval, should have some good sales, and enta may even have their own next gen non-rib, expanded genotype follow ons pan out so I agree it is undervalued